A pilot randomized controlled trial of ketamine in Borderline Personality Disorder.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology June 2023 Sarah K Fineberg, Esther Y Choi, Rosa Shapiro-Thompson et al.
This study is the first randomized controlled trial to test the effects of ketamine in Borderline Personality Disorder (BPD). BPD remains undertreated in the community and no medication has FDA approval for this indication. People with BPD experience chronic mood disturbances with depressed mood, suicidal ideation, and severe social difficulties. In this double-blind, randomized controlled...